# Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

> **NCT07349693** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Everfront Biotech Co., Ltd.** · enrollment: 175 (estimated)

## Conditions studied

- Recurrent Glioblastoma, IDH-Wildtype

## Interventions

- **DRUG:** Cerebraca wafer
- **DRUG:** Temozolomide (for relapsed malignant glioma)

## Key facts

- **NCT ID:** NCT07349693
- **Lead sponsor:** Everfront Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349693, "Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07349693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*